Find Zegocractin manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Cm-4620, 1713240-67-5, Zegocractin, Cm4620, Zegocractin [inn], Chembl4753998
Molecular Formula
C19H11ClF3N3O3
Molecular Weight
421.8  g/mol
InChI Key
QQMKTHUGOQDEIL-UHFFFAOYSA-N
FDA UNII
564AW1RR37

Zegocractin
Zegocractin is a calcium (Ca2+) release-activated channel (CRAC) inhibitor, with potential anti-inflammatory and protective activities. Upon administration, zegocractin targets, binds to and inhibits the calcium release-activated calcium channel protein 1 (Orai1), which forms the pore of CRAC, and is expressed on both parenchymal cells and immune cells. This prevents the transport of extracellular Ca2+ into the cell and inhibits the subsequent activation of Ca2+-mediated signaling and transcription of target genes. This may prevent Ca2+ entry-mediated cell death. It may also inhibit the proliferation of immune cells and prevents the release of various inflammatory cytokines in immune cells, such as interleukin-2 (IL-2) and tumor necrosis factor-alpha (TNF-a). This may lead to a reduction of inflammatory responses in inflammatory-mediated diseases. CRACs, specialized plasma membrane Ca2+ ion channels composed of the plasma membrane based Orai channels and the endoplasmic reticulum (ER) stromal interaction molecules (STIMs), mediate store operated Ca2+ entry (SOCE) and play a key role in calcium homeostasis. CRACs are overactivated in a variety of cell types, especially certain immune cells during inflammation, including T-lymphocytes, neutrophils and macrophages.
1 2D Structure

Zegocractin

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
N-[5-(6-chloro-2,2-difluoro-1,3-benzodioxol-5-yl)pyrazin-2-yl]-2-fluoro-6-methylbenzamide
2.1.2 InChI
InChI=1S/C19H11ClF3N3O3/c1-9-3-2-4-12(21)17(9)18(27)26-16-8-24-13(7-25-16)10-5-14-15(6-11(10)20)29-19(22,23)28-14/h2-8H,1H3,(H,25,26,27)
2.1.3 InChI Key
QQMKTHUGOQDEIL-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC1=C(C(=CC=C1)F)C(=O)NC2=NC=C(N=C2)C3=CC4=C(C=C3Cl)OC(O4)(F)F
2.2 Other Identifiers
2.2.1 UNII
564AW1RR37
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Auxora

2. Cm 4620

3. Cm-128

4. Cm-4620

5. Cm128

6. Cm4620

7. N-(5-(6-chloro-2,2-difluorobenzo(d)(1,3)dioxol-5-yl)pyrazin-2-yl)-2-fluoro-6-methylbenzamide

8. Zegocractin

2.3.2 Depositor-Supplied Synonyms

1. Cm-4620

2. 1713240-67-5

3. Zegocractin

4. Cm4620

5. Zegocractin [inn]

6. Chembl4753998

7. 564aw1rr37

8. N-[5-(6-chloro-2,2-difluoro-1,3-benzodioxol-5-yl)pyrazin-2-yl]-2-fluoro-6-methylbenzamide

9. Benzamide, N-(5-(6-chloro-2,2-difluoro-1,3-benzodioxol-5-yl)-2-pyrazinyl)-2-fluoro-6-methyl-

10. N-(5-(6-chloro-2,2-difluorobenzo(d)(1,3)dioxol-5-yl)pyrazin-2-yl)-2-fluoro-6-methylbenzamide

11. Cm 4620

12. Unii-564aw1rr37

13. Schembl18038390

14. Gtpl10087

15. Cm-4620 [who-dd]

16. Cm 4620 Pound>>cm4620

17. Dtxsid901337267

18. Bcp29536

19. Ex-a1898

20. Bdbm50575336

21. S6834

22. Compound I [wo2016138472a1]

23. Sb18686

24. Ac-35758

25. Bs-15636

26. Hy-101942

27. Cs-0022201

28. C73294

29. N-[5-(6-chloro-2,2-difluoro-1,3-benzodioxol-5-yl)-2-pyrazinyl]-2-fluoro-6-methylbenzamide

2.4 Create Date
2016-12-08
3 Chemical and Physical Properties
Molecular Weight 421.8 g/mol
Molecular Formula C19H11ClF3N3O3
XLogP34.3
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count8
Rotatable Bond Count3
Exact Mass421.0441034 g/mol
Monoisotopic Mass421.0441034 g/mol
Topological Polar Surface Area73.3 Ų
Heavy Atom Count29
Formal Charge0
Complexity617
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty